TG Therapeutics (TGTX) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

U.S. Net Product Revenue: Approximately $195 million, exceeding guidance of $185-$190 million and representing a 63% year-over-year increase.

Total Revenue: $205 million, including $201 million from global product sales and $3.6 million from licenses and royalties.

Operating Income: $34.8 million, significantly up from $8.6 million in Q1 2025.

Net Income: $19.8 million, or $0.12 per diluted share, compared to $5.1 million or $0.03 per diluted share in the prior year.

Cash Position: Ended the quarter with approximately $573 million in cash, reflecting an increase from about $200 million at year-end 2025.

2Strategic Updates and Business Highlights

BRIUMVI Performance: The company reported record-setting metrics across the board, with over 25,000 patients prescribed BRIUMVI globally. The treatment is showing sustained efficacy and favorable tolerability.

Pipeline Developments:

Phase III ENHANCE Study: Expected top-line data in the coming weeks, evaluating a simplified dosing schedule for BRIUMVI.

Subcutaneous (Subcu) BRIUMVI: Fully enrolled Phase III trial with expected top-line data by year-end 2026 or early 2027, targeting a potential 2028 launch.

Expansion into New Indications: Initiating studies in Myasthenia Gravis and treatment-resistant schizophrenia, alongside ongoing work with azer-cel in progressive MS.

Capital Allocation: Repurchased $100 million of shares during the quarter, with a total of approximately $200 million in buybacks since the program's inception.

3Forward Guidance and Outlook

Revenue Guidance: Full-year U.S. revenue guidance raised to $885 million to $900 million, with Q2 guidance targeting approximately $220 million in U.S. net revenue.

Operating Expenses: Expected to be around $350 million for the year, plus $100 million for subcutaneous manufacturing and secondary preparations.

4Bad News, Challenges, or Points of Concern

Competitive Pressures: The company acknowledges competition from established products and potential new entrants, particularly in the anti-CD20 market.

Market Dynamics: Concerns about how emerging therapies, such as remibrutinib, could impact BRIUMVI and the broader CD20 class, although management remains confident in BRIUMVI's positioning.

Operational Risks: The company faces risks associated with the timing of data readouts and regulatory approvals, which could affect future growth prospects.

5Notable Q&A Insights

Market Opportunity for Subcutaneous BRIUMVI: Management emphasized that the subcutaneous segment represents about 35% of the CD20 market, which they currently do not compete in, suggesting significant growth potential.

Persistence of Patients: There is growing confidence in the durability of BRIUMVI's patient retention, which is exceeding initial expectations and contributing to revenue stability.

DTC Campaign Impact: The direct-to-consumer campaign has shown positive indicators, driving patient awareness and demand for BRIUMVI.

Capital Allocation Strategy: Management remains disciplined in evaluating business development opportunities while continuing share repurchases, indicating a focus on maximizing shareholder value. Overall, TG Therapeutics reported a strong quarter with robust revenue growth and strategic advancements, while also navigating competitive challenges and operational risks.